Patients with BRAF V600E‐mutant glioma and BRAF V600E‐mutated biliary tract cancer benefited from the dabrafenib plus trametinib based on the results of the phase II ROAR trial.303, 304. This evidence concerns the gene BRAF and central nervous system cancer.